GF CSI All Share Health Care ETF

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

02656

159938

159929

512010

健康 160（2656.HK）现价 22.460，当日 +40.02%，盘中涨幅居港股前列，市值 79.1 亿。公司聚焦医疗健康与 AI 应用。数字医疗场景加速兑现，叠加 “流量中介” 到 “Token 工厂” 业务模式转型，多重利好刺激资金追捧。板块内科技赋能和市场主题驱动，推动健康 160 强势爆发。

Movers Alert

160 HEALTH

China Universal 800 Health Care ETF

E Fund CSI 300 Health Care ETF

Ping An Healthcare (2656.HK) Soars 40% on AI Momentum

00570

516930

588130

513120

159992

510660

512290

159316

520690

589720

Yesterday's closing price for China Traditional Chinese Medicine rose slightly by 1.19%, with a trading volume of approximately HKD 92 million, which is a slight increase compared to usual, reflecting the market's attention to its mid-term development prospects. The MACD daily line has not yet formed a clear strong bullish signal, but the latest dynamics in the electronic chemical pharmaceutical sector provide good visibility for it. Under the influence of news, the government's support for the traditional Chinese medicine industry is evident. With the continuous expansion of domestic healthcare demand and the increasing awareness of healthy living, the demand potential in the traditional Chinese medicine market is gradually being released. The company is further enhancing its market competitiveness through continuous research and development, innovation initiatives, and the expansion of its market network. Technically, the stock price trend remains stable above the mid-line trend level, reflecting that short-term positions are still primarily focused on position management. As market sentiment gradually recovers, if downward resistance diminishes, we can expect more significant liquidity changes and a positive drive for the market to refocus on the traditional Chinese medicine concept. The short-term trend is positively referenced, especially with the support of favorable industry prospects, traditional Chinese medicine concept stocks are not afraid of short-term market fluctuations. Caution is needed regarding the impact of the board's substantive decisions on stock prices, as well as the potential chain reaction from important economic indicators exceeding expectations. This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

TRAD CHI MED

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI HK Equities Medical and Health Integration ETF

GX CN MEDTECH

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Guotai SSE STAR Brand Name Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Pre-market trend | China Traditional Chinese Medicine (0570.HK) slightly warmed up on May 7, is there a hint of spring for the TCM concept?

06877

Top Eminent Healthcare Group received unanimous shareholder approval for all resolutions at its AGM on May 8, 2026, with 1.5 billion votes cast and no opposition. Shareholders endorsed the 2025 audited financial statements, re-elected four directors, and authorized the board to manage remuneration and share issuance. This reflects strong support for the company's governance and strategy, enhancing its capital management flexibility. Top Eminent Healthcare is a Cayman Islands-incorporated company listed in Hong Kong, focusing on healthcare-related businesses.

Tip Ranks

TE HEALTHCARE

Top Eminent Healthcare Wins Unanimous Shareholder Backing at AGM

601607

02607

588250

588860

159102

516500

Morgan Stanley has updated its risk-reward assessment on Shanghai Pharmaceuticals Holding, lowering its target price from HKD16 to HKD15.8 while maintaining an Overweight rating. The broker revised its earnings forecasts for 2026 to 2030 down by 2% to 3% due to a conservative revenue outlook. EPS is projected to reach RMB1.46 in 2026, RMB1.61 in 2027, and RMB1.72 in 2028.

AASTOCKS News

Shanghai Pharma

SH PHARMA

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP CSI Pharmaceuticals ETF

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts Shanghai Pharmaceuticals Holding  TP to HKD15.8, Rating Overweight

160 Health International Ltd. has expanded its "160AI Hospital" collaboration model to 102 public medical institutions in China, up from 82. This includes 54 Class IIIA hospitals, indicating strong traction in the high-end segment. The partner hospitals handle approximately 84.37 million outpatient visits and generate around RMB99.7 billion in revenue annually. The company is accelerating the deployment of its AI systems to enhance clinical workflows and support growth, while noting that performance may be affected by market and policy uncertainties.

160 Health Expands “160AI Hospital” Network to 102 Public Institutions in China

Floreo has submitted a De Novo request to the FDA for FloreoRx, a VR-based therapy for Autism Spectrum Disorder. This investigational device aims to support skill development in individuals with autism. The submission follows a pivotal trial demonstrating significant improvements in social communication skills among participants using FloreoRx compared to a control group. If authorized, FloreoRx could enhance access to effective autism therapy, addressing a critical need for families and clinicians. The trial involved 125 patients and showed high satisfaction rates among stakeholders, with no serious adverse events reported.

Fidelity

iShares US Pharma

VanEck Pharmaceutical ETF

Invesco Pharmaceuticals ETF

VG Health

SPDR Pharmac

Health Care Select Sector SPDR

BlackRock, Inc.

Ark Genomic Revolution ETF

iShares Global Healthcare

Following Pivotal Trial, FDA Set to Review First-of-a-Kind VR Autism Therapy

01666

03613

Recently, the National Chinese Herbal Pieces Alliance Procurement Office released centralized procurement documents, proposing to purchase 41 varieties of Chinese herbal pieces, categorized into two specification grades: selected goods and unified goods. This procurement follows the principles of 'stabilizing clinical use, ensuring quality, opposing internal competition, and preventing bid rigging,' led by the Shandong Medical Security Bureau, and is expected to reshape a market valued at 300 billion yuan

Wallstreetcn

TONG REN TANG

TONGRENTANGCM

CR Sanjiu

Taikang CNI Public Health and Medical Health ETF

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

M&T Bank Corp increased its position in McKesson Corporation (NYSE:MCK) by 263.9% in Q4, owning 83,674 shares after purchasing 60,683 additional shares. Other institutional investors also adjusted their stakes. Analysts maintain a positive outlook, with several firms issuing buy ratings and price targets ranging from $968 to $1,085. McKesson is expected to report strong earnings growth, and a recent deal with Apollo Funds for a minority stake in its Medical-Surgical Solutions business is seen as a positive step towards an IPO.

Market Beat

SPDR S&P Biotech

Proshares UltraShort Nasdaq Biotech

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

McKesson

M&T Bank

Apollo Global

Conmed

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

APOLLO GLOBAL MANAGEMENT INC 6.75% CONV PFD STK SER A

Apollo Global Management Pref Share APO 7.625 09/15/53

McKesson Corporation $MCK Position Increased by M&T Bank Corp

Bank of America Securities raised the target price for Shanghai Pharma to HKD 14 and reiterated a "Buy" rating. The report noted that Shanghai Pharma's total revenue last year was RMB 283.6 billion, a year-on-year increase of 3%, in line with expectations. Due to overall pricing pressure, the bank lowered its sales forecasts for 2026 to 2028 to 2.7%, 5.8%, and 2.1%, respectively

AASTOCKS

Bank of America Securities raises Shanghai Pharma's target price to 14 yuan, reiterates "Buy"

GF CSI All Share Health Care ETF(159938.SZ)